Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K

INTEGRATED BIOPHARMA INC

2023-Q2 EPS reported $0.05 revenue$24,580,000

Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.
Net loss of $55K ($0.00 per share) vs net income $1.0M ($0.04) in prior-year quarter.
Six-month revenue $24.6M (-9.9% YoY); net loss $90K vs income $1.5M.
Co-CEOs cite customer overstocking during pandemic as primary cause of sales decline.
Two largest customers in Contract Manufacturing Segment represent ~91% of total revenue.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTEGRATED BIOPHARMA INC reported the six-month period ended December 31, 2022 results: revenue $24.6 million, net income approximately $90,000, EPS $0.00 per share of common stock.

Period: the six-month period ended December 31, 2022
Revenue: $24.6 million
Net income: approximately $90,000
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

31, 2022 of approximately $33,000 and operating income of $0.7 million for the quarter ended December 31, 2021. Revenue for the six-month period ended December 31, 2022 was $24.6 million compared to $27.3 million for the six-month period ended December 31, 2021, a decrease of $2.7 million or 9.9%. The Company had an operating loss for the six-month period ended

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2022 results: revenue $12.3 million, net income approximately $55,000, EPS $0.00 per share of common stock.

Period: the quarter ended December 31, 2022
Revenue: $12.3 million
Net income: approximately $55,000
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2022. Revenue for the quarter ended December 31, 2022 was $12.3 million compared to $14.6 million for the quarter ended December 31, 2021, a decrease of $2.3 million or 15.6%. The Company had an operating loss for the quarter ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-23-003052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.